Cargando…
Considerations for adjuvant immunotherapy in stage II melanoma: KEYNOTE-716 and beyond
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477649/ https://www.ncbi.nlm.nih.gov/pubmed/37675306 http://dx.doi.org/10.21037/atm-23-839 |
| _version_ | 1785101179034796032 |
|---|---|
| author | Chen, Lanyi Nora Carvajal, Richard D. |
| author_facet | Chen, Lanyi Nora Carvajal, Richard D. |
| author_sort | Chen, Lanyi Nora |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10477649 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104776492023-09-06 Considerations for adjuvant immunotherapy in stage II melanoma: KEYNOTE-716 and beyond Chen, Lanyi Nora Carvajal, Richard D. Ann Transl Med Editorial Commentary AME Publishing Company 2023-03-13 2023-08-30 /pmc/articles/PMC10477649/ /pubmed/37675306 http://dx.doi.org/10.21037/atm-23-839 Text en 2023 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
| spellingShingle | Editorial Commentary Chen, Lanyi Nora Carvajal, Richard D. Considerations for adjuvant immunotherapy in stage II melanoma: KEYNOTE-716 and beyond |
| title | Considerations for adjuvant immunotherapy in stage II melanoma: KEYNOTE-716 and beyond |
| title_full | Considerations for adjuvant immunotherapy in stage II melanoma: KEYNOTE-716 and beyond |
| title_fullStr | Considerations for adjuvant immunotherapy in stage II melanoma: KEYNOTE-716 and beyond |
| title_full_unstemmed | Considerations for adjuvant immunotherapy in stage II melanoma: KEYNOTE-716 and beyond |
| title_short | Considerations for adjuvant immunotherapy in stage II melanoma: KEYNOTE-716 and beyond |
| title_sort | considerations for adjuvant immunotherapy in stage ii melanoma: keynote-716 and beyond |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477649/ https://www.ncbi.nlm.nih.gov/pubmed/37675306 http://dx.doi.org/10.21037/atm-23-839 |
| work_keys_str_mv | AT chenlanyinora considerationsforadjuvantimmunotherapyinstageiimelanomakeynote716andbeyond AT carvajalrichardd considerationsforadjuvantimmunotherapyinstageiimelanomakeynote716andbeyond |